ORIGINAL RESEARCH article

Front. Genet., 11 February 2020

Sec. Computational Genomics

Volume 11 - 2020 | https://doi.org/10.3389/fgene.2020.00042

Systematic Nucleotide Exchange Analysis of ESTs From the Human Cancer Genome Project Report: Origins of 347 Unknown ESTs Indicate Putative Transcription of Non-Coding Genomic Regions

  • 1. Aix Marseille Univ, IRD, APHM, SSA, VITROME, IHU-Méditerranée Infection, Marseille, France

  • 2. IHU-Méditerranée Infection, Marseille, France

  • 3. The National Natural History Collections, The Hebrew University of Jerusalem, Jerusalem, Israel

  • 4. Université Grenoble Alpes, Faculty of Medicine, Laboratory AGEIS EA 7407, Team Tools for e-Gnosis Medical & Labcom CNRS/UGA/OrangeLabs Telecoms4Health, La Tronche, France

Abstract

Expressed sequence tags (ESTs) provide an imprint of cellular RNA diversity irrespectively of sequence homology with template genomes. NCBI databases include many unknown RNAs from various normal and cancer cells. These are usually ignored assuming sequencing artefacts or contamination due to their lack of sequence homology with template DNA. Here, we report genomic origins of 347 ESTs previously assumed artefacts/unknown, from the FAPESP/LICR Human Cancer Genome Project. EST template detection uses systematic nucleotide exchange analyses called swinger transformations. Systematic nucleotide exchanges replace systematically particular nucleotides with different nucleotides. Among 347 unknown ESTs, 51 ESTs match mitogenome transcription, 17 and 2 ESTs are from nuclear chromosome non-coding regions, and uncharacterized nuclear genes. Identified ESTs mapped on 205 protein-coding genes, 10 genes had swinger RNAs in several biosamples. Whole cell transcriptome searches for 17 ESTs mapping on non-coding regions confirmed their transcription. The 10 swinger-transcribed genes identified more than once associate with cancer induction and progression, suggesting swinger transformation occurs mainly in highly transcribed genes. Swinger transformation is a unique method to identify noncanonical RNAs obtained from NGS, which identifies putative ncRNA transcribed regions. Results suggest that swinger transcription occurs in highly active genes in normal and genetically unstable cancer cells.

Introduction

Systematic nucleotide exchanges, also called swinger transformations, systematically exchange specific nucleotides with other specific nucleotides during DNA replication and/or RNA transcription. DNA or RNA molecules corresponding to systematic nucleotide changes are called swinger DNAs or swinger RNAs. Only 23 systematic nucleotide exchanges (Figure 1) are possible with four nucleotide bases (A, T, C and G), i.e. nine symmetric (X ↔ Y, e.g. A ↔ G) (; ) and 14 asymmetric (X → Y → Z → X, e.g. A → G → T → A) (; ). For example, in symmetric exchange A ↔ G, all As are replaced by Gs and all Gs by As. The 14 asymmetric exchanges are directional, e.g. A → G → T → A: all As are replaced by Gs, Gs by Ts and Ts by As. It is unclear whether these systematic exchanges occur during DNA/RNA polymerizations or result from posttranscriptional editions. Their relatively long lengths (> 100 nucleotides) favors the former. Previous correlation analyses (; ; ) show that the lengths and abundances of swinger RNAs are approximately proportional to rates calculated on the basis of corresponding single nucleotide misinsertions by the human mitochondrial gamma DNA polymerase (from ). This suggests that swinger RNAs result from polymerizations where the polymerase is stabilized in the usually transient, unstable state that causes regular single nucleotide misinsertions.

Figure 1

Systematic nucleotide exchange analyses identify genomic origins of unknown DNA/RNA sequences. Several types of RNAs with no sequence homology to template genomes exist. This includes RNA-DNA differences (; ; ; ; ; ; ; ; ), post-transcriptional editing (; ; ; ; ; ), post-transcriptional hyper editing () and polymerase template switching (; ). Transcript fusion explains some noncanonical RNAs (; ; ). Some rare DNAs and RNAs seerm to result from spontaneous, template-free polymerization (; ). Due to the systematic nature of swinger transformations, identified, previously unknown sequence reads overcome the widely argued possibility of by-chance alignment with randomly amplified sequencing artefacts since randomness does not produce systematic exchanges.

Mitogenomic human swinger RNA reads produced by Illumina confirmed corresponding EST data (). The swinger transcriptome of the amoeban-hosted Mimivirus was also confirmed by two different sequencing techniques (SOLID and 454, ). Detected peptides matching translation of the swinger-transformed mitogenome tend to map on detected swinger RNAs (; ; ; ). These findings were further confirmed in purified mitochondrial transcriptomes (), rejecting the possibility of cytoplasmic contamination. Chimeric mitochondrial swinger RNAs also exist, partly following swinger polymerization and partly regular polymerization, with abrupt switches between these parts (; ). This observation is paralleled by chimeric peptides, corresponding to translation of adjacent regular and swinger RNA (). Swinger RNA coverage associates with secondary structure formation (). Swinger DNA also occurs (; ). Molecular functions and associations of swinger polymerizations with healthy or unhealthy cells remain unknown. Recently, swinger RNAs with A ↔ T + C ↔ G transformation were identified in HIV mediated Non-Hodgkin's Lymphoma (). The identified RNAs with A ↔ T + C ↔ G transformation are similar to the transcriptional product by polymerase template switching, known in retroviruses () and the human genome ().

The Encyclopedia of DNA Elements (ENCODE) project concluded that a human genome includes approximately 20,000 protein-coding genes and predicts that 80% of non-coding regions regulate gene expression (). However, the transcriptomes generated by current RNA sequencing technologies do not cover the complete human genome, because analyses of sequencing reads assume only canonical transcription. Analyses assuming systematic nucleotide exchanges could identify non-canonical RNAs and their genomic origin.

Expressed sequence tags (ESTs) are short DNA sequences (100–600 bp) generated from the sequencing of cDNA libraries. The ESTs represent RNAs derived from a particular cell irrespective of sequence similarity or dissimilarity to its template genome, unlike transcriptomes, in which sequencing reads with sequence similarity are considered as true reads while ignoring non-homologous reads. This underlines a major limitation in identifying and studying non-canonical RNAs and their association with various genetic diseases like cancers. Therefore, here we apply swinger transformations to identify unknown expressed sequence tags (ESTs) occurring in the FAPESP/LICR Human Cancer Genome Project (). We expect to identify unknown ESTs reported in cancer cells, identify and report their genomic origins and confirm that swinger-transformed RNAs occur beyond mitochondria.

Methods

Identification of Unknown Ests

The FAPESP/LICR Human Cancer Genome Project corresponds to 891,011 published () and 55,248 unpublished ESTs in the NCBI database. These ESTs were blasted with the “Human genomic + transcript” database using the “highly similar sequence” algorithm (megablast) (; ). A total of 149,500 ESTs with no sequence similarity with the human genome were further blasted across all sequences in the NCBI database to exclude ESTs corresponding to potential contaminations.

Swinger Transformation of Unknown Ests

The unknown 149,500 ESTs were then swinger-transformed according to the 23 bijective transformations (Figure 1) (). These 149,500 unknown ESTs were blasted again with the “Human genomic + transcript” database using megablast, in order to detect their genomic template.

Results and Discussion

In total, 347 ESTs (0.23%) were identified using swinger transformation analyses (Tables 1–3). This rate is 4× lower than that estimated for human mitochondria (about 100/10000 ESTs, 1% (data from ; ; ). Swinger-transformed sequences of these identified 347 ESTs are in Supplementary Table 1. The remaining 99.77% of unidentified ESTs could be sequencing artefacts. These could also be ESTs with non-systematic post-transcriptional hyper editing () or resulting from systematic nucleotide deletion transcription (). Among 347 ESTs, 223 ESTs were symmetrically transformed swinger RNAs (219 ESTs were A ↔ T transformed, two ESTs were A ↔ C transformed, and one of each was C ↔ T and G ↔ T transformed). The average length of alignment of A ↔ T, A ↔ C, C ↔ T and G ↔ T transformed ESTs was 325 bp, 225 bp, 196 bp, 152 bp with an average percentage identity of 96.95, 90.52, 96.42, and 89.47% respectively. Similarly, A → T → C → G → A transformed asymmetric swinger transformations account for 124 ESTs with 96.95% average percentage identity and 308 bp average alignment length. The largest aligned swinger RNA was 685 bp with 41 bp as the smallest. Unlike symmetrical transformations, ESTs identified as A → T → C → G → A transformed have to be transcribed assuming A → G → C → T → A from the template DNA region (Figure 2). From here on, these identified ESTs are considered swinger RNAs. Abundances of swinger RNA classes are proportional to their mean length (r = 0.96, two tailed P = 0.00945). Assuming that different swinger classes result from different polymerase states, the positive correlation indicates that the same factor that promotes switching to a given mode of swinger transcription also favors the stability of this mode. The opposite, indicated by a negative association, would mean that frequent types of switches are unstable. We suggest that systematic nucleotide transformations happen during transcription (swinger transcription). This might result from polymerase enzyme fatigue. In carcinogenesis, during malignant transformation, cancer cells produce mutated RNAs and proteins because of genetic instability (; ). Therefore, swinger RNAs are probably mainly non- or dys-functional, and produce non- and dysfunctional proteins with probable carcinogenic effects.

Table 1

EST Acc No.BiosampleCancer tissueEST LengthSwinger transformationAligned sequence AIChromosomeGeneAligned Seq. length%IDe-value5'3'
AI902333.1SAMN00156544Breast173A ↔ CNM_001278462.112MDM2 proto-oncogene (MDM2)10097.0002.37e−3965163
AI903883.1SAMN00156581Breast193G ↔ TNM_080386.32tubulin alpha 3d (TUBA3D)14793.1974.39e−571,095950
AI939933.1SAMN00156800Colon283A ↔ TNM_001185092.11nitrilase 1 (NIT1)16894.6436.67e−67402238
AI939934.1*SAMN00156800Colon273A ↔ TNM_001037333.25cytoplasmic FMR1 interacting protein 2 (CYFIP2)20096.5001.80e−87738540
AI939935.1*SAMN00156800Colon156A ↔ TNM_001037333.25cytoplasmic FMR1 interacting protein 2 (CYFIP2)14295.7751.45e−58733592
AI939936.1*SAMN00156800Colon303A ↔ TNM_001037333.25cytoplasmic FMR1 interacting protein 2 (CYFIP2)20298.5151.78e−97741540
AI939937.1SAMN00156800Colon253A ↔ TNM_001008491.22septin 2 (SEPT2)23498.2916.26e−1122,9352,703
AI939938.1*SAMN00156800Colon266A ↔ TNM_001037333.25cytoplasmic FMR1 interacting protein 2 (CYFIP2)20294.0598.44e−81541741
AI939939.1SAMN00156800Colon377A ↔ TNW_019805496.111NADH:ubiquinone oxidoreductase core subunit S3 (NDUFS3)24698.3741.34e−11810,29410,049
AI939940.1SAMN00156800Colon361A ↔ TNM_001008491.22septin 2 (SEPT2)29994.3142.85e−1252,9052,608
AI939941.1SAMN00156801Colon303A ↔ TNM_001267774.117intraflagellar transport 20 (IFT20)22098.1821.05e−104609390
AI939942.1SAMN00156801Colon182A ↔ TNC_000008.118vir like m6A methyltransferase associated (VIRMA)7797.4035.45e−2894,525,71794,525,793
AI939943.1SAMN00156801Colon312A ↔ TNM_001282538.11G protein subunit beta 1 (GNB1)30196.0131.01e−1341,2121,512
AI939947.1*SAMN00156461Colon210A ↔ TNM_001009570.22chaperonin containing TCP1 subunit 7 (CCT7)18295.6045.08e−781,127946
AI939949.1*SAMN00156461Colon622A ↔ TNM_001009570.22chaperonin containing TCP1 subunit 7 (CCT7)57294.2310.05761,143
AI939950.1*SAMN00156461Colon512A ↔ TNM_001009570.22chaperonin containing TCP1 subunit 7 (CCT7)48498.3470.01,183702
AI939951.1*SAMN00156802Colon317A ↔ TNR_037849.12WW domain binding protein 1 (WBP1) INO80B-WBP1 readthrough (NMD candidate) (INO80B-WBP1), long non-coding RNA31094.8394.70e−1331,103796
AI939953.1SAMN00156802Colon609A ↔ TNM_001134671.28derlin 1 (DERL1)60897.8620.02,4071,802
AI939959.1*SAMN00156802Colon218A ↔ TNR_037849.12WW domain binding protein 1 (WBP1) INO80B-WBP1 readthrough (NMD candidate) (INO80B-WBP1), long non-coding RNA21997.7176.34e−1021,043826
AI939961.1*SAMN00156802Colon231A ↔ TNM_033017.37tripartite motif containing 4 (TRIM4)20495.5882.33e−862,4322,633
AI939962.1*SAMN00156802Colon212A ↔ TNM_001300821.212eukaryotic translation initiation factor 4B (EIF4B)16096.2506.67e−672,4342,276
AI939963.1*SAMN00156802Colon340A ↔ TNM_033017.37tripartite motif containing 4 (TRIM4)29195.1892.85e−1252,6292,344
AI939965.1SAMN00156802Colon214A ↔ TNR_038854.112negative regulator of antiviral response (non-protein coding) (NRAV), long non-coding RNA22094.5451.39e−88632848
AI939966.1*SAMN00156802Colon366A ↔ TNR_037849.12WW domain binding protein 1 (WBP1) INO80B-WBP1 readthrough (NMD candidate) (INO80B-WBP1), long non-coding RNA31794.6372.81e−1351,7172,032
AI939968.1SAMN00156802Colon270A ↔ TNC_000003.123CUB domain containing protein 1 (CDCP1)27098.8891.31e−13345,123,67445,123,943
AI939969.1*SAMN00156802Colon143A ↔ TNM_001300821.212eukaryotic translation initiation factor 4B (EIF4B)12398.3746.63e−542,3132,434
AI939970.1*SAMN00156802Colon255A ↔ TNM_033017.37tripartite motif containing 4 (TRIM4)23194.8051.04e−962,4062,633
AI939972.1SAMN00156802Colon168A ↔ TNC_000017.1117target of myb1 like 2 membrane trafficking protein (TOM1L2)16696.3861.39e−7017,849,62817,849,465
AI939973.1SAMN00156802Colon337A ↔ TNR_037616.16thioredoxin domain containing 5 (TXNDC5) and BLOC1S5-TXNDC5 readthrough (NMD candidate) (BLOC1S5-TXNDC5), long non-coding RNA34097.0594.42e−1601,8801,542
AI939976.1*SAMN00156802Colon200A ↔ TNR_037849.12WW domain binding protein 1 (WBP1) INO80B-WBP1 readthrough (NMD candidate) (INO80B-WBP1), long non-coding RNA200100.0001.34e−1001,7851,984
AI939980.1SAMN00156802Colon155A ↔ TNM_144570.216Jupiter microtubule associated homolog 2 (JPT2)15694.8723.04e−622,9492,794
AI939981.1*SAMN00156802Colon229A ↔ TNR_037849.12WW domain binding protein 1 (WBP1) INO80B-WBP1 readthrough (NMD candidate) (INO80B-WBP1), long non-coding RNA23596.1702.22e−1031,9961,762
AI939988.1*SAMN00156802Colon290A ↔ TNR_037849.12WW domain binding protein 1 (WBP1) INO80B-WBP1 read through (NMD candidate) (INO80B-WBP1), long non-coding RNA28096.7867.71e−1282,0211,744
AI940584.1*SAMN00156483Head_neck583A ↔ TNM_001166285.12chaperonin containing TCP1 subunit 7 (CCT7)56893.8380.01,8901,326
AW062762.1SAMN00156993Colon433A ↔ TNM_001354666.13peroxisome proliferator activated receptor gamma (PPARG), transcript40998.7780.01,1371,545
AW062764.1SAMN00156993Colon610A ↔ TNC_000002.122protein kinase C epsilon (PRKCE)49199.3890.045,959,85545,959,366
AW062765.1SAMN00156993Colon360A ↔ TNC_000009.129sorting nexin family member 30 (SNX30)34199.1202.01e−173112,811,006112,811,345
AW062769.1SAMN00156993Colon595A ↔ TNM_001198773.21phosphatidylinositol 4-kinase beta (PI4KB)46698.7120.03,1513,615
AW062770.1SAMN00156993Colon589A ↔ TNC_000016.1016Rho GTPase activating protein 17 (ARHGAP17)58699.1470.024,921,86224,922,445
AW062771.1SAMN00156993Colon643A ↔ TNM_006386.422DEAD-box helicase 17 (DDX17)60596.6940.01,8782,480
AW062772.1SAMN00156993Colon540A ↔ TNM_000381.3Xmidline 1 (MID1)51999.0370.05,7585,240
AW062773.1SAMN00156993Colon378A ↔ TNM_002795.317proteasome subunit beta 3 (PSMB3)36898.9130.0384751
AW062775.1SAMN00156993Colon650A ↔ TNM_000358.25transforming growth factor beta induced (TGFBI)32597.8462.05e−1581,1661,489
AW062776.1SAMN00156993Colon722A ↔ TXM_017008304.24PREDICTED: Homo sapiens RNA binding motif protein 47 (RBM47)35797.4799.36e−1721,9242,280
AW062777.1SAMN00156993Colon449A ↔ TNM_001345950.110tripartite motif containing 8 (TRIM8)11092.7274.07e−361,009901
AW062778.1SAMN00156993Colon491A ↔ TNC_000010.1110C-terminal binding protein 2 (CTBP2)47498.7340.0125,121,894125,121,421
AW062779.1SAMN00156993Colon252A ↔ TNM_001136153.16activating transcription factor 6 beta (ATF6B)23498.7186.09e−1141,2071,440
AW062782.1SAMN00156993Colon558A ↔ TNC_000008.118ArfGAP with SH3 domain, ankyrin repeat and PH domain 1 (ASAP1)35695.7873.41e−161130,131,998130,132,351
AW062784.1SAMN00156993Colon542A ↔ TNM_015397.39DDB1 and CUL4 associated factor 12 (DCAF12)32697.5464.45e−1552,7953,116
AW062787.1SAMN00156993Colon647A ↔ TNC_000012.1212signal transducer and activator of transcription 260891.7760.056,349,15656,348,551
AW062788.1SAMN00156993Colon458A ↔ TNC_000021.921VPS26 endosomal protein sorting factor C (VPS26C)29397.6114.54e−14037,236,57737,236,868
AW062789.1SAMN00156993Colon685A ↔ TNC_000017.1117Myosin XVIIIA (MYO18A)40698.2760.029,141,35829,141,763
AW062792.1SAMN00156993Colon688A ↔ TNM_001082480.28zinc finger protein 623 (ZNF623)67197.9140.03,0413,707
AW062793.1SAMN00156993Colon283A ↔ TNC_000007.147PREDICTED: Homo sapiens speedy/RINGO cell cycle regulator family member E2B (SPDYE2B)20684.4661.86e−49102,357,109102,357,313
AW062794.1SAMN00156993Colon115A ↔ TNM_001282507.116PKD1P4-NPIPA8 readthrough (PKD1P4-NPIPA8), non-coding RNA+ nuclear pore complex interacting protein family member A7 (NPIPA7)9896.9392.43e−38778875
AW062796.1SAMN00156993Colon196A ↔ TNM_001256410.110RAB18, member RAS oncogene family (RAB18)18398.3611.37e−858761,058
AW062799.1SAMN00156993Colon316A ↔ TNM_022130.35golgi phosphoprotein 3 (GOLPH3), transcript variant X1, mRNA27698.5511.27e−1351,1521,427
AW062801.1SAMN00156993Colon263A ↔ TNM_020700.112protein phosphatase, Mg2+/Mn2+ dependent 1H (PPM1H)24599.5926.00e−1244,9014,657
AW062802.1SAMN00156993Colon360A ↔ TNM_000610.311CD44 molecule (Indian blood group) (CD44),34697.3994.38e−1652,7992,454
AW062803.1SAMN00156993Colon642A ↔ TNM_005814.21glycoprotein A33 (GPA33), transcript variant X1, mRNA35192.8773.51e−1418251,171
AW062804.1SAMN00156993Colon640A ↔ TNM_000701.71ATPase Na+/K+ transporting subunit alpha 1 (ATP1A163696.8550.03,3942,760
AW062805.1SAMN00156993Colon622A ↔ TNC_000009.129golgi membrane protein 1 (GOLM1)40094.5001.55e−17486,074,94486,075,342
AW062807.1*SAMN00156993Colon616A ↔ TNM_001079524.14phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase (PAICS)58288.1440.01,7372,276
AW062808.1SAMN00156993Colon325A ↔ TNM_015658.32NOC2 like nucleolar associated transcriptional repressor (NOC2L)29098.6217.55e−1439531,242
AW062809.1SAMN00156993Colon609A ↔ TNM_001278699.23RNA polymerase II subunit H (POLR2H)54497.9780.01,2291,771
AW062815.1*SAMN00156993Colon621A ↔ TNW_017852933.116nuclear pore complex-interacting protein family member A7-like (LOC102724993)60698.5150.01,699,9091,699,305
AW062818.1SAMN00156993Colon363A ↔ TNC_000003.123coiled-coil-helix-coiled-coil-helix domain containing 6 (CHCHD6)34998.2817.23e−173126,914,442126,914,789
AW062819.1SAMN00156993Colon524A ↔ TNM_015658.31NOC2 like nucleolar associated transcriptional repressor (NOC2L)25299.6037.71e−1289911,242
AW062820.1*SAMN00156993Colon508A ↔ TNM_001293298.115cell migration inducing hyaluronidase 1 (CEMIP)38897.4230.06,4786,092
AW062821.1*SAMN00156993Colon336A ↔ TNM_002295.53ribosomal protein SA (RPSA)32995.4419.69e−147182510
AW062822.1SAMN00156993Colon350A ↔ TNM_007278.117GABA type A receptor-associated protein (GABARAP)15596.7741.09e−66650497
AW062823.1SAMN00156993Colon619A ↔ TNM_001300832.211FERM domain containing 8 (FRMD8)49998.9980.02,7512,253
AW062824.1SAMN00156993Colon294A ↔ TNM_001731.212BTG anti-proliferation factor 1 (BTG1), mRNA28997.9241.63e−1391,4101,122
AW062825.1SAMN00156993Colon358A ↔ TNM_002086.417growth factor receptor bound protein 2 (GRB2), transcr24698.7801.30e−1202,7933,038
AW062826.1SAMN00156993Colon311A ↔ TNC_000007.147PREDICTED: Homo sapiens speedy/RINGO cell cycle regulator family member E2B (SPDYE2B)20684.4661.86e−49102,357,109102,357,313
AW062827.1SAMN00156993Colon500A ↔ TNM_014455.31ring finger protein 115 (RNF115)38099.4740.01,064685
AW062828.1SAMN00156993Colon490A ↔ TNM_001271969.16heat shock protein 90 alpha family class B member 1 (HSP90AB1),36498.0771.54e−1792,0911,730
AW062829.1SAMN00156993Colon588A ↔ TNM_001024216.21filamin binding LIM protein 1 (FBLIM1)52599.0480.02,3542,877
AW062830.1SAMN00156993Colon191A ↔ TNM_003302.27thyroid hormone receptor interactor 6 (TRIP6)17396.5324.98e−751,6391,467
AW062831.1SAMN00156993Colon157A ↔ TNM_003749.213insulin receptor substrate 2 (IRS2), mRNA14494.4445.12e−555,6435,503
AW175732.1*SAMN00156993Colon392A ↔ TNC_000015.1015cell migration inducing hyaluronidase 1 (CEMIP)23796.2031.72e−10480,878,82880,879,064
AW175733.1SAMN00156993Colon748A ↔ TNM_032833.41protein phosphatase 1 regulatory subunit 15B (PPP1R15B)57495.6450.071643
AW175736.1SAMN00156993Colon391A ↔ TNM_005080.322X-box binding protein 1 (XBP1)28497.1832.13e−133497779
AW175738.1*SAMN00156993Colon195A ↔ TNC_000003.123chromosome 3 open reading frame 14 (C3orf14)13795.6206.63e−5462,332,40662,332,270
AW175740.1*SAMN00156993Colon382A ↔ TNC_000008.118pericentriolar material 1 (PCM1)28897.9172.11e−13817,968,41517,968,700
AW175741.1SAMN00156993Colon277A ↔ TNC_000002.122phosphodiesterase 11A (PDE11A)20395.5673.80e−86177,849,206177,849,004
AW175742.1SAMN00156993Colon701A ↔ TNC_000001.111nuclear receptor subfamily 5 (NR5A2)19098.4211.75e−89200,040,067200,040,255
AW175747.1*SAMN00156993Colon182A ↔ TNC_000012.1212ribosomal protein SA pseudogene 52 (RPSAP52)12292.6235.23e−4065,765,19365,765,313
AW175749.1SAMN00156993Colon379A ↔ TNC_000003.122tigger transposable element also zinc finger protein 621 (ZNF621) derived 1 (TIGD1)24498.3617.82e−1183,165,2993,165,056
AW175751.1SAMN00156993Colon403A ↔ TNT_187585.111potassium voltage-gated channel subfamily Q member 1 (KCNQ1)33694.0484.54e−14049,60549,278
AW175753.1SAMN00156993Colon800A ↔ TNC_000005.105MCC regulator of WNT signaling pathway (MCC)14084.2866.87e−29113,144,132113,144,267
AW176932.1*SAMN00156993Colon655A ↔ TNM_001079524.14phosphoribosylaminoimidazole carboxylase and phosphoribosylaminoimidazolesuccinocarboxamide synthase (PAICS)62497.9170.02,4261,803
AW176933.1*SAMN00156993Colon286A ↔ TNC_000012.1212ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 228397.1733.56e−131110,285,901110,285,620
AW176934.1*SAMN00156993Colon294A ↔ TNC_000012.1212ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 228599.6493.49e−146110,285,904110,285,620
AW176938.1SAMN00156993Colon183A ↔ TNM_014280.21DnaJ heat shock protein family (Hsp40) member C8 (DNAJC8),17996.6486.40e−79661483
AW176940.1SAMN00156993Colon334A ↔ TNC_000014.914serine palmitoyltransferase long chain base subunit 2 (SPTLC2)30698.6932.68e−15277,544,60777,544,912
AW176941.1SAMN00156993Colon664A ↔ TNC_000002.122MIR4435-2 host gene (MIR4435-2HG)58098.2760.0111,301,721111,302,299
AW176942.1SAMN00156993Colon337A ↔ TNM_001265603.115mortality factor 4 like 1 (MORF4L1)27998.2084.57e−135565843
AW176943.1SAMN00156993Colon627A ↔ TNC_000016.1016membrane bound transcription factor peptidase, site 1(MBTPS1)50098.2000.084,061,14284,061,638
AW176945.1SAMN00156993Colon361A ↔ TNM_030629.216c-Maf inducing protein (CMIP)32698.4669.49e−1622,7752,450
AW176946.1SAMN00156993Colon664A ↔ TNM_001873.34carboxypeptidase E (CPE)30798.0465.79e−1491,193890
AW176947.1SAMN00156993Colon680A ↔ TNC_000004.124huntingtin (HTT)66098.4850.03,200,4163,201,074
AW176948.1SAMN00156993Colon360A ↔ TNM_001256799.212glyceraldehyde-3-phosphate dehydrogenase (GAPDH)31199.3572.05e−1588311,140
AW176949.1SAMN00156993Colon304A ↔ TNM_005731.32actin related protein 2/3 complex subunit 2 (ARPC2)27294.1187.87e−113867597
AW176952.1SAMN00156993Colon629A ↔ TNC_000002.122integrin subunit alpha 6 (ITGA6)63099.8410.0172,430,001172,429,372
AW176953.1SAMN00156993Colon375A ↔ TNM_001204510.117SENP3-EIF4A1 readthrough (NMD candidate) (SENP3-EIF4A1), long non-coding RNA+eukaryotic translation initiation factor 4A1 (EIF4A1)33899.4085.59e−174824487
AW176954.1SAMN00156993Colon282A ↔ TNM_006761.417tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein epsilon (YWHAE),non-coding RNA26498.4852.14e−128961699
AW176955.1SAMN00156993Colon470A ↔ TNC_000007.1410general transcription factor IIi264100.0003.54e−13674,722,57474,722,311
AW176958.1SAMN00156993Colon255A ↔ TNM_001291484.219carcinoembryonic antigen related cell adhesion molecule 5 (CEACAM5)22799.1191.02e−1111,1301,356
AW176959.1*SAMN00156993Colon682A ↔ TNM_001402.56eukaryotic translation elongation factor 1 alpha 1 (EEF1A1)64792.4270.09231,566
AW176960.1*SAMN00156993Colon622A ↔ TNM_001402.56eukaryotic translation elongation factor 1 alpha 1 (EEF1A1)61099.6720.08911,499
AW176962.1SAMN00156993Colon309A ↔ TNM_005514.76major histocompatibility complex, class I, B (HLA-B)27697.4641.28e−1301,3381,063
AW176963.1*SAMN00156993Colon451A ↔ TNC_000001.111erythrocyte membrane protein band 4 (EPB41)38198.1630.029,114,29429,113,915
AW176964.1*SAMN00156993Colon392A ↔ TNC_000001.111erythrocyte membrane protein band 4 (EPB41)38198.6880.029,114,29429,113,915
AW176965.1SAMN001569931Colon628A ↔ TNM_001137604.22RNA polymerase I subunit B (POLR1B)42199.0500.03,1593,579
AW176968.1SAMN00156993Colon633A ↔ TNM_001172663.116RAB40C, member RAS oncogene family (RAB40C)16098.7501.79e−741,8011,643
AW176969.1SAMN00156993Colon348A ↔ TNM_002588.35protocadherin gamma subfamily B, 3 (PCDHGB3)35097.7141.57e−1694,4004,051
AW176971.1*SAMN00156993Colon650A ↔ TNM_001402.56eukaryotic translation elongation factor 1 alpha 1 (EEF1A1)30798.6977.44e−1531,3051,000
AW176972.1SAMN00156993Colon374A ↔ TNM_001167671.23LIM domain containing preferred translocation partner in lipoma (LPP)36998.1030.016,85917,225
AW176973.1SAMN00156993Colon645A ↔ TNC_000016.1016zinc and ring finger 1 (ZNRF1)58798.9780.075,058,19775,058,783
AW176974.1SAMN00156993Colon652A ↔ TNM_001276418.19SEC16 homolog A, endoplasmic reticulum export factor (SEC16A)58599.3160.08,6958,111
AW176982.1*SAMN00156993Colon560A ↔ TNC_012920.1mitocox151399.2200.06,5376,025
AW903505.1*SAMN00159106Nervous_normal436A → T → C → G → ANR_148543.12clathrin heavy chain linker domain containing 1 (CLHC1)43798.1690.05691,001
AW903508.1SAMN00159106Nervous_normal443A → T → C → G → ANM_015018.36DOP1 leucine zipper like protein A (DOP1A)36299.4480.07,6257,264
AW903509.1*SAMN00159106Nervous_normal449A → T → C → G → ANM_001351724.14Rap guanine nucleotide exchange factor 2 (RAPGEF2)45197.5610.05,9546,400
AW903510.1SAMN00159106Nervous_normal472A → T → C → G → ANM_004859.317clathrin heavy chain (CLTC)40699.0150.03,7994,202
AW903511.1SAMN00159106Nervous_normal464A → T → C → G → ANC_000014.914endoplasmic reticulum oxidoreductase 1 alpha (ERO1A)44497.9730.052,686,67752,687,114
AW903512.1*SAMN00159106Nervous_normal185A → T → C → G → ANM_024996.53G elongation factor mitochondrial 1 (GFM1)18690.3239.61e−613,4463,264
AW903513.1*SAMN00159106Nervous_normal254A → T → C → G → ANM_024996.53G elongation factor mitochondrial 1 (GFM1)166100.0002.60e−813,2373,072
AW903514.1*SAMN00159106Nervous_normal423A → T → C → G → ANM_001351724.14Rap guanine nucleotide exchange factor 2 (RAPGEF2)42499.0570.05,9626,384
AW903515.1SAMN00159106Nervous_normal447A → T → C → G → ANC_000008.118mitochondrial calcium uptake family member 3447100.0000.017,028,84917,028,403
AW903516.1*SAMN00159106Nervous_normal446A → T → C → G → ANM_007353.27G protein subunit alpha 12 (GNA12)40999.5110.03,8414,249
AW903517.1*SAMN00159106Nervous_normal382A → T → C → G → ANM_004529.39MLLT3, super elongation complex subunit (MLLT3)37999.7360.04,7554,377
AW903518.1*SAMN00159106Nervous_normal261A → T → C → G → ANC_012920.1mitocox113399.2489.61e−616,6346,766
AW903519.1*SAMN00159106Nervous_normal457A → T → C → G → ANC_000001.111membrane associated guanylate kinase (MAGI3)44397.0650.0113,403,203113,403,645
AW903520.1SAMN00159106Nervous_normal461A → T → C → G → ANR_029435.114PSMA3 antisense RNA 1 (PSMA3-AS1), long non-coding RNA447100.0000.02,4261,980
AW903521.1*SAMN00159106Nervous_normal449A → T → C → G → ANC_012920.1mitocox145198.6700.06,5346,982
AW903523.1SAMN00159106Nervous_normal447A → T → C → G → ANC_000004.124NEDD4 binding protein 2 (N4BP2)44599.7750.040,063,37540,063,375
AW903524.1*SAMN00159106Nervous_normal455A → T → C → G → ANM_001286691.19MLLT3, super elongation complex subunit (MLLT3)449100.0000.04,6714,223
AW903525.1SAMN00159106Nervous_normal431A → T → C → G → ANC_000003.123C-X9-C motif containing 1 (269)26999.6282.40e−13628,242,97028,242,702
AW903526.1*SAMN00159106Nervous_normal466A → T → C → G → ANR_029435.114PSMA3 antisense RNA 1 (PSMA3-AS1) and long non-coding RNA45699.7810.02,4261,971
AW903527.1*SAMN00159106Nervous_normal446A → T → C → G → ANM_004529.39MLLT3, super elongation complex subunit (MLLT3)44699.7760.04,2134,658
AW903528.1*SAMN00159106Nervous_normal461A → T → C → G → ANR_148543.12clathrin heavy chain linker domain containing 1 (CLHC1)45799.3440.01,034578
AW903529.1SAMN00159106Nervous_normal464A → T → C → G → ANR_049782.12sorting nexin 17 (SNX17)45598.9010.01,025573
AW903530.1SAMN00159106Nervous_normal418A → T → C → G → ANM_004800.213transmembrane 9 superfamily member 2 (TM9SF2)39598.7340.02,5092,115
AW903531.1SAMN00159106Nervous_normal408A → T → C → G → ANC_000022.1122phosphatidylinositol 4-kinase alpha (PI4KA)40797.5430.020,799,22520,799,629
AW903532.1SAMN00159106Nervous_normal279A → T → C → G → ANC_000003.123zinc finger protein 148 (ZNF148)19498.9695.50e−93125,335,569125,335,762
AW903533.1*SAMN00159106Nervous_normal473A → T → C → G → ANM_001293092.17G protein subunit alpha 12 (GNA12)40999.2670.03,7904,198
AW903534.1*SAMN00159106Nervous_normal469A → T → C → G → ANC_000007.147ataxin 7 like 1 (ATXN7L1)46199.1320.0105,869,501105,869,961
AW903537.1SAMN00159106Nervous_normal448A → T → C → G → ANC_000016.1016RNA binding fox-1 homolog 1 (RBFOX1)43199.3040.06,537,4836,537,913
AW903538.1SAMN00159106Nervous_normal454A → T → C → G → ANC_000023.11Xeuroligin 4 X-linked (NLGN4X)45499.5590.06,115,5546,115,102
AW903539.1*SAMN00159106Nervous_normal321A → T → C → G → ANC_000011.1011chromosome 11 open reading frame 80 (C11orf80)24893.9529.08e−10166,766,91466,767,161
AW903540.1SAMN00159106Nervous_normal329A → T → C → G → ANC_000007.147family with sequence similarity 221 member A (FAM221A)329100.0006.36e−17223,695,68523,696,013
AW903541.1*SAMN00159106Nervous_normal470A → T → C → G → ANC_000005.105teneurin transmembrane protein 2 (TENM2)45599.3410.0167,499,052167,499,506
AW903542.1*SAMN00159106Nervous_normal464A → T → C → G → ANM_024996.53G elongation factor mitochondrial 1 (GFM1)45599.5600.02,9803,434
AW903543.1SAMN00159106Nervous_normal470A → T → C → G → ANC_000001.111vacuolar protein sorting 72 homolog (VPS72)46899.3590.0151,182,693151,183,160
AW903544.1*SAMN00159106Nervous_normal458A → T → C → G → ANM_018947.57cytochrome c, somatic (CYCS), mRNA46099.1300.0703245
AW903545.1*SAMN00159106Nervous_normal458A → T → C → G → ANC_000005.105teneurin transmembrane protein 2 (TENM2)45999.7820.0167,499,058167,499,516
AW903546.1SAMN00159106Nervous_normal236A → T → C → G → ANC_000011.1011GRB2 associated binding protein 2 (GAB2)15497.4032.05e−6778,340,98778,341,140
AW903547.1*SAMN00159106Nervous_normal441A → T → C → G → ANC_000001.111membrane associated guanylate kinase (MAGI3)42797.1900.0113,403,203113,403,629
AW903550.1SAMN00159106Nervous_normal460A → T → C → G → ANM_172350.21CD46 molecule (CD46)46299.1340.02,9712,510
AW903551.1*SAMN00159106Nervous_normal215A → T → C → G → ANC_012920.1mitocox110999.0832.11e−477,4167,308
AW903553.1SAMN00159106Nervous_normal468A → T → C → G → ANM_001351562.19TLE family member 4 (TLE4)46997.6550.041764643
AW903554.1*SAMN00159106Nervous_normal357A → T → C → G → ANM_018947.57cytochrome c, somatic (CYCS), mRNA35599.1550.0682328
AW903556.1*SAMN00159106Nervous_normal444A → T → C → G → ANM_004529.39MLLT3, super elongation complex subunit (MLLT3)44699.3270.04,7464,301
AW903557.1SAMN00159106Nervous_normal458A → T → C → G → ANC_000012.1212synaptotagmin 1 (SYT1)46298.7010.079,289,39479,288,933
AW903558.1SAMN00159106Nervous_normal476A → T → C → G → ANC_000012.1212kinesin family member 21A (KIF21A)47799.1610.039,406,69939,407,174
AW903559.1SAMN00159106Nervous_normal453A → T → C → G → ANC_000017.1117dynein axonemal heavy chain 17 (DNAH17)29099.3106.59e−14778,428,31778,428,606
AW903560.1SAMN00159106Nervous_normal459A → T → C → G → ANC_000006.126capping protein regulator and myosin 1 linker 1 (CARMIL1)40396.0300.025,338,78025,338,379
AW903561.1*SAMN00159106Nervous_normal463A → T → C → G → ANC_000014.914PSMA3 antisense RNA 1 (PSMA3-AS1) and long non-coding RNA44998.8860.058,265,82958,265,381
AW903563.1*SAMN00159106Nervous_normal427A → T → C → G → ANM_001352634.18pericentriolar material 1 (PCM1)42399.2910.05,9546,376
AW903564.1SAMN00159106Nervous_normal457A → T → C → G → ANM_025054.48valosin containing protein interacting protein 1 (VCPIP1)37499.1980.07,6037,976
AW903565.1*SAMN00159106Nervous_normal434A → T → C → G → ANC_000007.147ataxin 7 like 1 (ATXN7L1)42799.2970.0105,869,531105,869,956
AW903566.1SAMN00159106Nervous_normal283A → T → C → G → ANM_015541.23leucine rich repeats and immunoglobulin like domains 1 (LRIG1)19098.4211.54e−883,4473,258
AW903567.1SAMN00159106Nervous_normal444A → T → C → G → ANC_000022.1122RNA binding fox-1 homolog 2 (RBFOX2)34492.4423.11e−13535,867,77935,868,118
AW903568.1SAMN00159106Nervous_normal428A → T → C → G → ANM_020755.36serine incorporator 1 (SERINC1)32699.0801.07e−1642,3322,008
AW903570.1SAMN00159106Nervous_normal454A → T → C → G → ANT_187614.117aminopeptidase puromycin sensitive pseudogene (NPEPPS1)20097.0001.54e−882,236,5402,236,343
AW903571.1SAMN00159106Nervous_normal480A → T → C → G → ANM_001242866.221protein arginine methyltransferase 2 (PRMT2)29799.6631.82e−1521,248952
AW903573.1*SAMN00159106Nervous_normal336A → T → C → G → ANC_012920.1mitocox123698.7291.15e−1147,1127,347
AW903576.1SAMN00159106Nervous_normal472A → T → C → G → ANM_203401.14stathmin 1 (STMN1)46898.9320.0361827
AW903577.1SAMN00159106Nervous_normal466A → T → C → G → ANC_000007.147LUC7 like 2 (LUC7L2), pre-mRNA splicing factor46198.9150.0139,362,483139,362,023
BE085177.1*SAMN00159564Breast269A → T → C → G → ANC_000010.1110protein tyrosine phosphatase receptor type E (PTPRE)24298.3476.87e−117127,960,155127,959,914
BE085178.1SAMN00159564Breast176A → T → C → G → ANM_015888.41hook microtubule tethering protein 1 (HOOK1)17192.9822.67e−612,1852,024
BE085183.1SAMN00159564Breast293A → T → C → G → ANC_000010.1110SMC5-SMC6 complex localization factor 2 (SLF2)9295.6525.99e−33100,947,017100,947,107
BE085186.1*SAMN00159564Breast302A → T → C → G → ANM_002840.41protein tyrosine phosphatase, receptor type F (PTPRF)26896.6422.45e−1212,9852,724
BE085188.1SAMN00159564Breast280A → T → C → G → ANM_007042.43ribonuclease P/MRP subunit p14 (RPP14)19396.3731.55e−83328139
BE085197.1SAMN00159564Breast196A → T → C → G → ANM_001281724.23biotinidase (BTD)10699.0572.73e−462,2752,170
BE085202.1SAMN00159564Breast170A → T → C → G → ANM_021009.612ubiquitin C (UBC)10289.2161.01e−251,8691,772
BE145238.1SAMN00157869Head_neck333A ↔ TNM_001042465.210prosaposin (PSAP)33497.9041.50e−1631,7392,072
BE145239.1*SAMN00157869Head_neck293A ↔ TNM_001104629.14chromosome 4 open reading frame 19 (C4orf19)29297.2605.59e−1381,8282,119
BE145240.1SAMN00157869Head_neck169A ↔ TNM_001033925.110TIA1 cytotoxic granule associated RNA binding protein like 1 (TIAL1)16996.4504.73e−741,0131,181
BE145242.1SAMN00157869Head_neck452A ↔ TNM_022470.33zinc finger matrin-type 3 (ZMAT3)40498.2670.06,2736,675
BE145243.1SAMN00157869Head_neck110A ↔ TNM_001101662.11nardilysin convertase (NRDC)11099.0911.76e−481,4451,336
BE145245.1SAMN00157869Head_neck421A ↔ TNC_000005.105small integral membrane protein 3 (SMIM3)41697.8370.0150,784,346150,784,758
BE145246.1SAMN00157869Head_neck266A ↔ TNM_001033047.24nephronectin (NPNT)26792.8849.75e−106391656
BE145247.1SAMN00157869Head_neck359A ↔ TNW_019805496.111mitochondrial carrier 2 (MTCH2)35696.0675.39e−16355,68256,035
BE145248.1*SAMN00157869Head_neck247A ↔ TNC_000014.914valosin containing protein lysine methyltransferase (VCPKMT)24092.0839.96e−9150,108,37850,108,617
BE145250.1*SAMN00157869Head_neck289A ↔ TNC_000014.914valosin containing protein lysine methyltransferase (VCPKMT)29095.5171.58e−12850,108,28550,108,574
BE145251.1SAMN00157869Head_neck329A ↔ TNC_000009.129spectrin alpha, non-erythrocytic 1 (SPTAN1)33096.0619.15e−151128,610,482128,610,155
BF332836.1SAMN00160205Breast298A → T → C → G → ANC_000001.111putative homeodomain transcription factor 1 (PHTF1)23095.6524.22e−99113,710,355113,710,126
BF332837.1SAMN00160205Breast376A → T → C → G → ANC_000002.122BCL2 like 11(BCL2 L11)24198.3403.20e−115111,159,962111,160,199
BF332838.1SAMN00160205Breast359A → T → C → G → ANC_000008.118integrator complex subunit 9 (INTS9)23797.4681.16e−10928,784,74828,784,981
BF332840.1SAMN00160205Breast300A → T → C → G → ANM_018364.41round spermatid basic protein 1 (RSBN1)20994.7371.20e−843,2673,062
BF332841.1SAMN00160205Breast372A → T → C → G → ANM_002266.317karyopherin subunit alpha 2 (KPNA2)26996.6546.82e−1222,0221,757
BF332842.1SAMN00160205Breast378A → T → C → G → ANM_003761.42vesicle associated membrane protein 8 (VAMP8)25399.2098.76e−126296548
BF332846.1SAMN00160205Breast280A → T → C → G → ANM_017409.312homeobox C10 (HOXC10)19095.7894.35e−791,9581,773
BF332847.1SAMN00160205Breast405A → T → C → G → ANC_000007.1473-hydroxyisobutyrate dehydrogenase (HIBADH)27597.8182.42e−13127,629,86927,629,596
BF332849.1SAMN00160205Breast308A → T → C → G → ANC_000014.914dishevelled associated activator of morphogenesis 1 (DAAM1)20695.6311.99e−8759,268,77559,268,570
BF332850.1SAMN00160205Breast383A → T → C → G → ANC_000012.1212spermatogenesis associated serine rich 2 (SPATS2)29696.2844.02e−13449,458,04649,457,752
BF332851.1SAMN00160205Breast335A → T → C → G → ANC_000013.1113SMAD family member 9 (SMAD9)24998.3948.83e−12136,916,21436,916,462
BF332854.1SAMN00160205Breast293A → T → C → G → ANC_000003.123coiled-coil domain containing 66 (CCDC66)22198.1904.19e−10456,561,67056,561,451
BF332855.1SAMN00160205Breast309A → T → C → G → ANC_000014.914RAD51 paralog B (RAD51B)22296.3961.97e−9768,178,42268,178,203
BF353453.1SAMN00161174Head_neck395A ↔ TNM_002274.317keratin 13 (KRT13)53100.0008.30e−191,6791,627
BF354529.1*SAMN00160318Head neck397A → T → C → G → ANM_015596.219kallikrein related peptidase 13 (KLK13)31798.1071.09e−1541,3481,664
BF354541.1SAMN00160318Head neck363A → T → C → G → ANM_030634.21zinc finger protein 436 (ZNF436)29598.6448.52e−1463,9154,209
BF354544.1SAMN00160318Head neck449A → T → C → G → ANC_000006.126protein phosphatase 1 regulatory subunit 10 (PPP1R10)38498.6980.030,600,71530,601,097
BF354553.1SAMN00160318Head neck387A → T → C → G→ ANW_016107297.15GUSB Pseudogene (GUSBP1)33298.1931.79e−162163,285162,954
BF354559.1SAMN00160318Head neck193A → T → C → G → AXM_011524110.317small G protein signaling modulator 2 (SGSM2)9993.9395.99e−332,4572,360
BF354564.1*SAMN00160318Head neck402A → T → C → G → ANM_015596.219kallikrein related peptidase 13 (KLK13)30698.3661.09e−1491,3591,664
BF354572.1SAMN00160318Head neck389A → T → C → G → AXM_011514699.26glucose-fructose oxidoreductase domain containing 1 (GFOD1)34698.8443.80e−1743,0083,353
BF370229.1SAMN00160862Prostate_normal282A → T → C → G → ANM_000138.415fibrillin 1 (FBN1)12795.2765.87e−488,2638,388
BF370230.1SAMN00160862Prostate_normal282A → T → C → G → ANM_006887.415ZFP36 ring finger protein like 2 (ZFP36L2)34697.3993.85e−1642,5442,201
BF370232.1SAMN00160862Prostate_normal410A → T → C → G → ANC_012920.1mitoatp635998.3296.31e−1778,6639,020
BF370233.1SAMN00160862Prostate_normal437A → T → C → G → ANC_000023.11xubiquitin specific peptidase 9 X-linked (USP9X)37398.9280.041,186,36041,185,989
BF370234.1SAMN00160862Prostate_normal413A → T → C → G → ANC_000012.1212lysine demethylase 5A (KDM5A)34997.9942.96e−170326,420326,075
BF370235.1SAMN00160862Prostate_normal294A → T → C → G → ANM_001288733.117testis expressed 2 (TEX2)12798.4259.68e−564,5334,659
BF370236.1SAMN00160862Prostate_normal294A → T → C → G → ANC_000009.129basonuclin 2 (BNC2)19498.9695.50e−9316,514,55716,514,750
BF370237.1SAMN00160862Prostate_normal423A → T → C → G → ANM_001146227.18ribosomal protein S20 (RPS20)30499.0136.54e−152493191
BF370238.1SAMN00160862Prostate_normal332A → T → C → G → ANC_000004.124sec1 family domain containing 2 (SCFD2)24398.3542.47e−11652,874,27652,874,518
BF370239.1SAMN00160862Prostate_normal355A → T → C → G → ANM_018046.45angiogenic factor with G-patch and FHA domains 1 (AGGF1)29398.2941.43e−1434,0584,350
BF370241.1SAMN00160862Prostate_normal305A → T → C → G → ANC_000017.1117tubulin folding cofactor D (TBCD)17398.8442.60e−8182,761,45882,761,630
BF370242.1SAMN00160862Prostate_normal250A → T → C → G → ANC_000001.111GNG12, DIRAS3 and WLS antisense RNA 1 (GNG12-AS1) and Wnt ligand secretion mediator (WLS)12798.4259.68e−5668,182,91868,182,792
BF370243.1SAMN00160862Prostate_normal413A → T → C → G → ANC_000005.105ubiquitin conjugating enzyme E2 D2 (UBE2D2)27297.0598.76e−126139,610,960139,610,690
BF798643.1SAMN00162090Colon_ins420A ↔ TNR_045104.115integrator complex subunit 14 (INTS14)29092.7595.75e−114163448
BF798647.1SAMN00162090Colon_ins415A ↔ TNC_012920.1mito12s27194.0963.46e−111915649
BF798651.1SAMN00162090Colon_ins363A ↔ TNM_032593.29histidine triad nucleotide binding protein 2 (HINT2)5794.7375.12e−15429484
BF798653.1SAMN00162090Colon_ins425A ↔ TNC_012920.1mito12s27094.8155.75e−114649915
BF798654.1SAMN00162090Colon_ins375A ↔ TNM_001291920.19retinoid X receptor alpha (RXRA)13695.5888.10e−532,0402,170
BF798660.1SAMN00162090Colon_ins464A ↔ TNC_012920.1mito12s26997.3981.22e−125649915
BF798665.1SAMN00162090Colon_ins485A ↔ TNM_004069.419adaptor related protein complex 2 sigma 1 subunit (AP2S1)37398.1230.0564193
BF798667.1SAMN00162090Colon_ins521A ↔ TNM_005561.313lysosomal associated membrane protein 1 (LAMP1)48195.8420.0392872

List of swinger transformed ESTs identified using BLAST. The list includes ESTs identified using swinger transformations and mapped on genes identified only in one biosamples.

Genes corresponding to more than one EST sequence are indicated by *.

Table 2

EST Acc No.BiosampleCancer tissueLength of ESTSwinger transformationAcc. No. of aligned sequenceChrom-osomeGeneAligned Seq. length%IDevalue5'3'
BE085181.1SAMN00159564Breast109A → T → C → G → ANC_012920.1mito16s4195.1226.21e−082,8852,924
BE085203.1SAMN00159564Breast282A → T → C → G → ANC_012920.1mito16s18998.4131.54e−881,9501,764
BE085205.1SAMN00159564Breast134A → T → C → G → ANC_012920.1mito16s8997.7531.29e−342,8822,794
BE085207.1SAMN00159564Breast245A → T → C → G → ANC_012920.1mito16s18597.8381.20e−842,8383,021
BF332839.1SAMN00160205Breast249A → T → C → G → ANC_012920.1mito16s15697.4365.70e−682,2582,105
BF798658.1SAMN00162090Colon_ins624A ↔ TNC_012920.1mito16s+trnaL+ND146498.2760.03,0753,537
BF798678.1SAMN00162090Colon_ins589A ↔ TNC_012920.1mito16s+trnaL+ND146497.4140.03,0753,537
AI939948.1SAMN00156461Colon529A ↔ TNM_000476.29adenylate kinase 1 (AK1)50497.0240.0198700
AI940588.1SAMN00156483Head_neck650A ↔ TNM_001318121.19adenylate kinase 1 (AK1)57498.6060.0177749
BF332844.1SAMN00160205Breast251A → T → C → G → ANM_000100.321cystatin B (CSTB)17096.4717.32e−72452287
AW176935.1SAMN00156993Colon386A ↔ TNC_000021.921cystatin b (CSTB)34999.1402.58e−17743,774,23743,774,583
AW176936.1SAMN00156993Colon368A ↔ TNC_000021.921cystatin b (CSTB)34899.4255.55e−17943,774,23743,774,583
AW903549.1SAMN00159106Nervous_normal444A → T → C → G → ANM_001308390.118DLG associated protein 1 (DLGAP1)44699.3270.04,9084,464
AW176970.1SAMN00156993Colon701A ↔ TNC_000020.1120DLG associated protein 4 (DLGAP4)68598.6860.036,525,99036,526,674
BF332852.1SAMN00160205Breast406A → T → C → G → ANM_153201.311heat shock protein family A (Hsp70) member 8 (HSPA8)30297.3511.84e−142925626
BF798649.1SAMN00162090Colon_ins529A ↔ TNM_006597.511heat shock protein family A (Hsp70) member 8 (HSPA8)48695.0620.0386865
AW062795.1SAMN00156993Colon639A ↔ TNM_005120.2Xmediator complex subunit 12 (MED12)50299.8010.04,4753,974
BF332843.1SAMN00160205Breast340A → T → C → G → ANM_005121.217mediator complex subunit 13 (MED13)21498.1319.08e−101943731
BF332848.1SAMN00160205Breast372A → T → C → G → ANM_001271811.112mediator complex subunit 21 (MED21)24597.9592.47e−1161,097854
AW176957.1SAMN00156993Colon517A ↔ TNC_012920.1mitond149599.1920.03,6634,157
BF798657.1SAMN00162090Colon_ins363A ↔ TNC_012920.1mitond121093.3331.30e−803,3333,537
AW903507.1SAMN00159106Nervous_normal215A → T → C → G → ANC_012920.1mitond221499.5332.51e−1064,7394,952
BF332853.1SAMN00160205Breast308A → T → C → G → ANC_012920.1mitond221699.0749.02e−1064,7244,939
BF354531.1SAMN00160318Head neck373A → T → C → G → ANC_012920.1mitond224298.7601.48e−1184,4824,723
BF354537.1SAMN00160318Head neck345A → T → C → G → ANC_012920.1mitond2232100.0005.31e−1184,4924,723
BI032899.1SAMN00162655Nervous_normal424A ↔ CNC_012920.1mitond235184.0462.80e−875,3715,033
AI939946.1SAMN00156461Colon488A ↔ TNC_012920.1mitond239397.7100.05,0624,670
AI939952.1SAMN00156802Colon263A ↔ TNC_012920.1mitond223695.3398.21e−1014,9584,723
AI939954.1SAMN00156802Colon252A ↔ TNC_012920.1mitond222596.4442.95e−1004,9454,723
AI939955.1SAMN00156802Colon212A ↔ TNC_012920.1mitond211399.1151.14e−494,9054,794
AI939956.1SAMN00156802Colon200A ↔ TNC_012920.1mitond218698.3876.48e−874,9304,746
AI939957.1SAMN00156802Colon269A ↔ TNC_012920.1mitond221897.7062.28e−1014,7514,967
AI939958.1SAMN00156802Colon223A ↔ TNC_012920.1mitond219896.4656.48e−874,9194,723
AI939960.1SAMN00156802Colon286A ↔ TNC_012920.1mitond224594.6942.28e−1014,9624,723
AI939964.1SAMN00156802Colon251A ↔ TNC_012920.1mitond222996.0702.95e−1004,9494,723
AI939967.1SAMN00156802Colon281A ↔ TNC_012920.1mitond224597.5513.74e−1144,7234,967
AI939971.1SAMN00156802Colon251A ↔ TNC_012920.1mitond224092.5001.36e−904,9624,723
AI939974.1SAMN00156802Colon243A ↔ TNC_012920.1mitond223194.8053.74e−964,9524,723
AI939975.1SAMN00156802Colon152A ↔ TNC_012920.1mitond215296.7115.05e−654,8984,748
AI939977.1SAMN00156802Colon226A ↔ TNC_012920.1mitond220195.5221.37e−854,9224,723
AI939978.1SAMN00156802Colon212A ↔ TNC_012920.1mitond218897.3401.77e−844,9144,729
AI939979.1SAMN00156802Colon162A ↔ TNC_012920.1mitond216395.7063.02e−674,9494,789
AI939982.1SAMN00156802Colon248A ↔ TNC_012920.1mitond223395.7083.72e−1014,9554,723
AI939984.1SAMN00156802Colon233A ↔ TNC_012920.1mitond221494.3932.93e−874,9334,723
AI939985.1SAMN00156802Colon145A ↔ TNC_012920.1mitond212296.7211.86e−494,8474,967
AI939986.1SAMN00156802Colon166A ↔ TNC_012920.1mitond216393.8658.45e−634,8914,729
AI940581.1SAMN00156483Head_neck533A ↔ TNC_012920.1mitond239299.4900.04,6715,062
AI940582.1SAMN00156483Head_neck509A ↔ TNC_012920.1mitond239399.2370.04,6705,062
AI940585.1SAMN00156483Head_neck475A ↔ TNC_012920.1mitond239496.7010.04,6705,062
AI940586.1SAMN00156483Head_neck296A ↔ TNC_012920.1mitond229498.2995.83e−1444,6924,984
AI940587.1SAMN00156483Head_neck474A ↔ TNC_012920.1mitond239399.2370.05,0624,670
BF354521.1SAMN00160318Head neck383A → T → C → G → ANC_012920.1mitond434395.3352.35e−15111,01611,354
CK327105.1SAMN00157633Colon474A ↔ TNC_012920.1mitond439199.2330.011,61111,999
BF370011.1SAMN00160853Prostate normal252C ↔ TNC_012920.1mitond419696.4292.65e−8511,61011,801
AW062763.1SAMN00156993Colon624A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)38797.6740.01,8821,497
AW062774.1SAMN00156993Colon673A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)40599.7530.01,8891,485
AW062781.1SAMN00156993Colon197A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)18699.4621.36e−901,7071,523
AW062786.1SAMN00156993Colon583A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)40599.0120.01,8891,485
AW062790.1SAMN00156993Colon685A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)40595.3090.01,8881,485
AW062791.1SAMN00156993Colon533A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)40599.0120.01,8891,485
AW062797.1SAMN00156993Colon331A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)32199.0652.64e−1621,4851,805
AW062798.1SAMN00156993Colon312A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)30397.6901.25e−1451,5031,805
AW062806.1SAMN00156993Colon472A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)40999.5110.01,8931,485
AW062810.1SAMN00156993Colon625A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)62599.5200.02,4301,806
AW062811.1SAMN00156993Colon426A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)40599.7530.01,4851,889
AW062812.1SAMN00156993Colon420A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)40499.2570.01,4861,889
AW062813.1SAMN00156993Colon688A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)405100.0000.01,8891,485
AW062814.1SAMN00156993Colon443A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)40599.0120.01,4851,889
AW062816.1SAMN00156993Colon536A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)40599.7530.01,4851,889
AW062817.1SAMN00156993Colon250A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)22193.6654.91e−851,5741,781
AW176937.1SAMN00156993Colon360A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)34697.9777.29e−1681,4851,825
AW176944.1SAMN00156993Colon603A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)40599.0120.01,8891,485
AW176950.1SAMN00156993Colon419A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)86100.0003.15e−371,8041,889
AW176951.1SAMN00156993Colon192A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)142100.0002.33e−681,7481,889
AW176956.1SAMN00156993Colon348A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)31999.0603.41e−1611,4851,803
AW176966.1SAMN00156993Colon497A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)40599.5060.01,8891,485
AW176967.1SAMN00156993Colon158A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)15997.4841.39e−701,9172,074
AW176975.1SAMN00156993Colon481A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)37397.8550.01,4851,854
AW176976.1SAMN00156993Colon605A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)35488.7012.17e−1181,8341,485
AW176977.1SAMN00156993Colon639A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)40599.2590.01,8891,485
AW176978.1SAMN00156993Colon434A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)40799.0170.01,4851,889
AW176979.1SAMN00156993Colon599A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)40699.5070.01,4851,889
AW176980.1SAMN00156993Colon426A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)40599.0120.01,4851,889
AW176981.1SAMN00156993Colon599A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)40599.0120.01,8891,485
BF333938.1SAMN00157869Head_neck665A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)79100.0002.92e−331,5631,485
BF333939.1SAMN00157869Head_neck611A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)31998.7461.89e−1591,8031,485
BF333940.1SAMN00157869Head_neck509A ↔ TNM_002568.38poly(A) binding protein cytoplasmic 1 (PABPC1)31191.3184.33e−1161,7921,485

List of ESTs based on the genes identified in more than one biosample.

Table 3

EST Acc No.BiosampleCancer tissueLength of ESTSwinger transformationAcc No of aligned sequenceChromosomeGeneAligned Seq. length%IDevalue5'3'
AI939983.1SAMN00156802Colon379A ↔ TNC_000009.129Non-coding region36097.7784.32e−175120,855,4821,21E+08
AI939987.1SAMN00156802Colon367A ↔ TNC_000009.129Non-coding region34597.9717.29e-168120,855,4641,21E+08
AW062766.1SAMN00156993Colon457A ↔ TNC_000016.1016Non-coding region31399.6819.49e−16274,318,75574319067
AW175734.1SAMN00156993Colon328A ↔ TNC_000004.124Non-coding region13690.4411.12e−41131,268,2241,31E+08
AW175735.1SAMN00156993Colon620A ↔ TNC_000004.124Non-coding region19195.2881.78e−79131,268,1671,31E+08
AW175739.1SAMN00156993Colon222A ↔ TNC_000008.118Non-coding region13997.1221.83e−59102,600,3461,03E+08
AW175744.1SAMN00156993Colon506A ↔ TNC_000008.118Non-coding region31397.7643.46e−15188,009,95988,009,648
AW903506.1SAMN00159106Nervous_normal422A → T → C → G → ANC_000006.126Non-coding region35097.1438.28e−166132,009,1301,32E+08
AW903535.1SAMN00159106Nervous_normal440A → T → C → G → ANC_000013.1113Non-coding region44299.3210.095,650,10495,650,545
AW903555.1SAMN00159106Nervous_normal434A → T → C → G → ANC_000010.1110Non-coding region43699.3120.020,554,18720,553,752
AW903569.1SAMN00159106Nervous_normal430A → T → C → G → ANC_000004.124Non-coding region35798.5991.36e−17817,483,41417,483,770
AW903572.1SAMN00159106Nervous_normal248A → T → C → G → ANC_000013.1113Non-coding region56100.0003.66e−2095,650,46195,650,406
BE085219.1SAMN00159564Breast314A → T → C → G → ANC_000003.123Non-coding region31197.7493.94e−149169,791,1911,7E+08
BF332859.1SAMN00160205Breast211A → T → C → G → ANC_000020.1120Non-coding region14390.2102.12e−4259,862,27359,862,140
BF332861.1SAMN00160205Breast364A → T → C → G → ANC_000010.1110Non-coding region25697.2664.11e−1198,810,0148,810,267
BF354533.1SAMN00160318Head neck388A → T → C → G → ANC_000005.105Non-coding region33199.6982.29e−17169,932,96869,933,298
BF370228.1SAMN00160862Prostate_normal264A → T → C → G → ANC_000023.11xNon-coding region19595.8972.01e−82136,928,8791,37E+08
AW062783.1SAMN00156993Colon640A ↔ TNC_000009.129Uncharacterized LOC10192708655775.4045.09e−6070,473,45570,472,931
BF798648.1SAMN00162090Colon_ins344A ↔ TNC_000003.123Uncharacterized LOC10272351214896.6222.87e−624,006,8724,006,726

List of ESTs mapped on non-coding genomic regions and uncharacterized genes.

Figure 2

Swinger-Transformed Genes in Different Cancer Tissues

These 347 swinger-transformed RNAs matched 205 known and two uncharacterized genes (Tables 1–3). These identified swinger RNAs might be artefacts. However, among these 207 genes, swinger RNAs from 10 genes were detected in multiple cancer types and biosamples (Table 2). These genes are adenylate kinase 1 (AK1), cystatin B (CSTB), DLG associated protein (DLGAP), heat shock protein family A (Hsp70) member 8 (HSPA8), mediator complex subunits (MED), poly(A) binding protein cytoplasmic 1 (PABPC1), MT-16s rRNA, MT-ND1, MT-ND2 and MT-ND4.

Two A ↔ T-transformed swinger RNAs detected in the colon and head-neck cancer lines mapped on the adenylate kinase 1 (AK1) coding gene (Table 2). AK1 plays an important role in tumor suppression and it is often downregulated in cancer cells (; ; ; ). Three swinger RNAs detected in breast (A → G → C → T → A) and two colon cancer (A ↔ T) lines mapped on cystatin B (CSTB) (Table 2). CSTB plays an important role in expression and epigenetic regulation and is downregulated in lung, gastric and colorectal cancers (; ). CSTB promotes cell proliferation, migration and suppresses apoptosis in gastric cancer cells (). Downregulation of CSTB also promotes gastric cancer (). Similarly, swinger RNAs for HSPA8 and PABPC1 were identified. We identified two swinger RNAs from the HSPA8 protein-coding region. The carboxy-terminus of Hsc70 interacting protein (CHIP) plays an important role in cancer initiation and progression (; ; ) and has an anti-tumor effect in many cancer types including colon and gastric cancers (; ; ; ; ; ). Thirty-three swinger RNAs were transcribed from the PABPC1 gene from colon cancer and head-neck cancer biosamples, respectively (Table 2). PABPC proteins are RNA processing proteins associated with gene expression regulation () and are upregulated in prostate and colorectal cancers (). PABPC also has a tumor suppressor role in head and neck squamous cell carcinoma (). Swinger-transformed RNAs produced from these identified genes will produce non-homologous and putatively nonfunctional mRNAs translating dysfunctional nonhomologous proteins, which supports the association between downregulation of these genes and cancer cell types. These swinger RNAs could be early stage factors responsible for cancer induction or result from genetic instability in later stages of malignant cancers (; ). Results favor the former because the swinger transformed mRNA of tumor suppressor genes would result in disruption of gene function inhibiting programmed cell death. Analyses also identify two swinger RNAs mapped on DLG associated proteins (DLGAP1 and DLGAP4) coding genes in healthy nervous tissue samples and colon cancer cells. DLGAP is a protein overexpressed in the brain () and promotes invasiveness in cancer cell lines (). Similarly, three swinger RNAs were transcribed from mediator complex subunit genes (MED) in colon and breast cancer tissues (Table 2). Mutations in MED12 are associated with tumorigenesis (; ) and cause benign breast fibroepithelial lesions (). These two observations suggest that swinger transformation of MED should induce carcinogenesis, whereas, swinger RNAs are transcribed from overexpressing DLGAP genes due to enzyme fatigue in cancer cells.

Among the detected swinger RNAs, 51 swinger RNAs match mitochondrial genes (Tables 1 and 2). It is widely known and proven that mitochondrial genes are overexpressed in various cancer types to meet up the metabolic requirements of cancer cells and are strongly associated with cancer (; ; ; ). Among 51 swinger RNAs, 7, 1, 30 and 3 swinger RNAs are transcribed from mitochondrial 16s rRNA, ND1, ND2 and ND4, respectively. These were identified in several biosamples (Table 2). Sixty-six percent (33 ESTs) of the identified swinger RNAs were transcribed from the MT-ND region. A previous study showed bias for swinger transformation of MT-ND genes ().

Interestingly, detection of swinger transformed DLGAP1 mRNAs (overexpressed ~15× in neurons compared to other tissue cells; ), in normal nervous tissue samples suggests that the swinger transformation is not directly associated with cancer but perhaps associated with highly expressed genes. Carcinogenesis could be the outcome of swinger transformed dysfunctional mRNAs. Previously identified swinger RNAs from highly active cancer-associated genes () also support this finding. Indeed, even within mitochondrial genes, rRNAs are more expressed than other genes, and swinger rRNAs are the most frequently observed mitochondrial swinger RNAs in previous publications (; ; ; ), matching the pattern of positive association between regular and swinger transcriptions. Hence, the positive association between expression and swinger transformation occurs independently for human nuclear and mitochondrial genes. Hence, at least at this qualitative level of analysis, observations on these highly expressed nuclear and mitochondrial genes support that swinger transformations associate with highly active genomic regions that result in cancer induction and progression due to nonfunctional transcripts.

In order to test whether swinger transformations are biased towards some regions of genes, genes for which swinger RNAs were detected in more than one biosample (Table 2) are regionally compartmentalized in three equal regions i.e. 5' region, mid region and 3' regions, each region spanning 1/3 of the gene. Mitochondrial genes like 16S rRNA (five of seven ESTs), ND4 (two of three ESTs), and nuclear gene Cystatin B (three of three ESTs) mapped on the 3' extremity of their respective genes.

Among the 30 ESTs mapped on ND2 gene across multiple biosamples, 28 mapped on the central region (5' to 3'; 4,692 to 4,984 bp) of the mitochondrial genome (NC_012920.1), while two mapped on the 5' terminal of ND2 (4,482–4723 bp) gene. Interestingly, for MT-ND4, among the three ESTs identified across three different biosamples for three different swinger transformations, two ESTs mapped on the same 3' terminal ND4 region i.e. 11,610–11,801 bp on the mitochondrial genome (NC_012920.1). For Nuclear gene poly(A) binding protein cytoplasmic 1 (PABPC1), all the 33 identified ESTs preferentially mapped on the mid-region (5' 1,485 bp to 3' 1,803 bp on NM_002568.3) of PABPC1 gene.

Considering mitochondrial and nuclear genes separately, 38 among 43 (mitochondrial, 88.4%, one tailed sign test P = 0.0011) and 33 among 33 (nuclear, 100%, one tailed sign test P = 1.6 × 10−6) swinger RNAs map either on the mid or the 3' regions of the gene. These tests assume that the probability of mapping randomly on these regions is 2/3. One tailed sign tests are justified by the working hypothesis that polymerase enzyme fatigue (occurring more downstream from transcription initiation) causes swinger transcription. These observations indicate that the mid and 3' regions of highly expressed genes are more prone to produce swinger transformed RNAs than the 5' region, for each nuclear and mitochondrial genes. Similarly, swinger transformed ESTs (from only one biosample) mapping on identified genes, preferentially mapped on the same region (Table 1 shows the 5' and 3' positions of such ESTs).

Among 275 ESTs from nuclear protein coding genes, 196 ESTs mapped on exons of genes and 76 swinger transformed ESTs mapped on gene introns. Three ESTs mapped partly on gene exons and partly on introns, suggesting that swinger transformations occur before post transcriptional modification, and support our working hypothesis of swinger polymerization during replication/transcription.

The 347 ESTs correspond to 203 protein coding genes and 19 RNAs from non-coding regions. The median and mean size of a protein coding gene in human genome are ~26,288 bp and ~66,577 bp (). The mean and median length of identified 203 swinger transformed protein coding genes (including mitochondrial genes) are 124,427 bp and 55,291 bp which is almost twice the mean and median lengths of human protein coding genes. These genes for which swinger transcripts were detected also included the largest protein coding gene in the human genome i.e. RNA binding fox-1 homolog 1 (RBFOX1). These observations indicate that swinger transformation probably due to polymerase fatigue is not only associated to highly active genes but could also associate with large genes. This could also explain the biased mapping of swinger RNAs on the mid and 3' regions of genes, vs the first third of genes.

Swinger RNAs From Non-Coding and Uncharacterized Genomic Regions

Seventeen and two identified swinger RNAs were transcribed from 15 non-coding genomic regions and two uncharacterized genomic regions, respectively (Table 3). The 15 non-coding swinger RNAs were not from 5' or 3' UTR or intronic regions of protein-coding genes. To test if these 15 identified genomic regions on various human chromosomes are transcriptionally active, we did a transcriptome search in seventy-one samples (SRX768406–SRX768476, ) with the identified swinger RNAs transcribed from these non-coding genomic regions. Good and complete alignments of the reads on the searched sequences confirmed transcriptions of these 15 non-coding regions (Supplementary Table 2). This result suggests that these 15 regions are transcriptionally active, with potential roles in nerve cells and possible associations with carcinogenesis. However, these specific cancer tissue samples are unavailable, preventing further in-vitro and in-vivo tests and analyses.

The identified swinger RNAs were mapped on human nuclear chromosomes. No compartmentalizations on any chromosomal arm, region or band of a chromosome were detected in relation to swinger expressed regions. Swinger RNAs produced by transformations that are more conservative at the amino acid level are also more abundant than swinger RNAs produced by transformations that cause more amino acid changes (). This effect was also observed when comparing transformations involving the same number of nucleotides in the transformation (2, 3 or 4). For the distribution of swinger RNAs detected in the present study, too few classes of transformations were detected to enable such subdivisions. However, when considering all transformations, conservation increases with swinger RNA abundances (r = 0.4187, one tailed P = 0.0234). C ↔ G is the least conservative among the transformations involving only two nucleotides, and is one among two transformations for which no swinger RNA was detected in the currently examined data.

Conclusion

We report genomic origins of 347 previously unidentified ESTs generated by the FAPESP/LICR Human Cancer Genome Project (). These represent 0.23% of the 149,500 unidentified ESTs from that project. Note that other types of systematic transformations apparently produce non-canonical RNAs, such as systematic deletions, which produce so-called delRNAs (; ; ; ; ) and corresponding peptides (; ; ; ; ; ), including chimeric peptides (). This underlines a general approach to identify unknown sequences generated by various sequencing methods. This study identifies swinger RNAs transcribed from multiple cancer-associated genes (Tables 1 and 2), suggesting highly active genes produce swinger transcripts possibly due to enzyme fatigue and promoting cancer progression. The identified sequences might be sequencing artefacts. However, random artefacts generated by sequencing equipment could not produce systematic exchanges. Systematic sequencing errors should produce swinger RNAs for all sequenced ESTs, however, biosamples where swinger RNAs are detected include regular canonical RNAs. Analyses also identify transcriptionally active non-coding regions on human chromosomes discovering putative ncRNA transcribing regions with potentially significant roles in normal and cancer cells. We provide a unique method to study and identify unknown sequencing reads, reducing loss of important genetic information in raw sequence data. Systematic editing of RNA might contribute to solve the dark DNA conundrum.

Funding

This work was supported by the A*MIDEX project (no ANR-11-IDEX-0001-02) funded by the « Investissements d'Avenir » French Government program, managed by the French National Research Agency (ANR).

Statements

Data availability statement

All datasets generated for this study are included in the article/Supplementary Material.

Author contributions

GW conducted design, analysis, observation and writing. P-EF contributed to result assessments. HS designed the systematic nucleotide exchange framework. P-EF and HS contributed to writing and supervising this study.

Acknowledgments

We thank the reviewers for helpful and constructive comments on earlier draft of the manuscript.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fgene.2020.00042/full#supplementary-material

Supplementary Table 1

Swinger transformed version of 347 ESTs mapped on human genome.

Supplementary Table 2

Whole cell transcriptome BLAST result for swinger transformed ESTs mapped on non coding genomic region.

References

  • 1

    AhmedS. F.DebS.PaulI.ChatterjeeA.MandalT.ChatterjeeU.et al. (2012). The chaperone-assisted E3 ligase C terminus of Hsc70-interacting protein (CHIP) targets PTEN for proteasomal degradation. J. Biol. Chem.287, 15996–16006. doi: 10.1074/jbc.M111.321083

  • 2

    BéguinP.GillS.CharpinN.ForterreP. (2015). Synergistic template-free synthesis of dsDNA by Thermococcus nautili primase PolpTN2, DNA polymerase PolB, and pTN2 helicase. Extremophiles19 (1), 69–76. doi: 10.1007/s00792-014-0706-1

  • 3

    BahnJ. H.LeeJ. H.LiG.GreerC.PengG.XiaoX. (2012). Accurate identification of A-to-I RNA editing in human by transcriptome sequencing. Genome Res.22, 142–150. doi: 10.1101/gr.124107.111

  • 4

    Bar-YaacovD.AvitalG.LevinL.RichardsA. L.HachenN.Rebolledo JaramilloB.et al. (2013). RNA-DNA differences in human mitochondria restore ancestral form of 16S ribosomal RNA. Genome Res.23, 1789–1796. doi: 10.1101/gr.161265.113

  • 5

    BassB. L. (2002). RNA editing by adenosine deaminases that act on RNA. Annu. Rev. Biochem.71, 817–846. doi: 10.1146/annurev.biochem.71.110601.135501

  • 6

    BlankA.GallantJ. A.BurgessR. R.LoebL. A. (1986). An RNA polymerase mutant with reduced accuracy of chain elongation. Biochemistry25, 5920–5928. doi: 10.1021/bi00368a013

  • 7

    BullerdiekJ.RommelB. (2018). Factors targeting MED12 to drive tumorigenesis?F1000Research7, 359. doi: 10.12688/f1000research.14227.1

  • 8

    ChenC.BundschuhR. (2012). Systematic investigation of insertional and deletional RNA-DNA differences in the human transcriptome. BMC Genomics13, 616. doi: 10.1186/1471-2164-13-616

  • 9

    CioccaD. R.CalderwoodS. K. (2005). Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones10 (2), 86–103. doi: 10.1379/CSC-99r.1

  • 10

    CollavinL.LazarevičD.UtreraR.MarzinottoS.MonteM.SchneiderC. (1999). wt p53 dependent expression of a membrane-associated isoform of adenylate kinase. Oncogene18, 5879–5888. doi: 10.1038/sj.onc.1202970

  • 11

    DunhamI.KundajeA.AldredS. F.CollinsP. J.DavisC. A.DoyleF.et al. (2012). An integrated encyclopedia of DNA elements in the human genome. Nature489 (7414), 57–74. doi: 10.1038/nature11247

  • 12

    EisermannK.DarJ. A.DongJ.WangD.MasoodiK. Z.WangZ. (2015). Poly (A) binding protein cytoplasmic 1 is a novel co-regulator of the androgen receptor. PloS One10 (7), e0128495. doi: 10.1371/journal.pone.0128495

  • 13

    El HoumamiN.SeligmannH. (2017). Evolution of nucleotide punctuation marks: from structural to linear signals. Front. Genet.27, 8. doi: 10.3389/fgene.2017.00036

  • 14

    FagerbergL.HallstromB. M.OksvoldP.KampfC.DjureinovicD.OdebergJ.et al. (2014). Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol. Cell. Proteomics13(2), 397–406. doi: 10.1074/mcp.M113.035600

  • 15

    GarzonR.VoliniaS.PapaioannouD.NicoletD.KohlschmidtJ.YanP. S.et al. (2014). Expression and prognostic impact of lncRNAs in acute myeloid leukemia. Proc. Natl. Acad. Sci. U. S. A.111 (52), 18679–18684. doi: 10.1073/pnas.1422050112

  • 16

    GaudeH.AznarN.DelayA.BresA.Buchet-PoyauK.CaillatC.et al. (2012). Molecular chaperone complexes with antagonizing activities regulate stability and activity of the tumor suppressor LKB1. Oncogene31, 1582–1591. doi: 10.1038/onc.2011.342

  • 17

    HatakeyamaS.WatanabeM.FujiiY.NakayamaK. I. (2005). Targeted destruction of c-Myc by an engineered ubiquitin ligase suppresses cell transformation and tumor formation. Cancer Res.65, 7874–7879. doi: 10.1158/0008-5472.CAN-05-1581

  • 18

    JanY. H.LaiT. C.YangC. J.HuangM. S.HsiaoM. (2019). A co-expressed gene status of adenylate kinase 1/4 reveals prognostic gene signature associated with prognosis and sensitivity to EGFR targeted therapy in lung adenocarcinoma. Sci. Rep.9 (1), 12329. doi: 10.1038/s41598-019-48243-9

  • 19

    JanssenE.KuiperJ.HodgsonD.ZingmanL. V.AlekseevA. E.TerzicA.et al. (2004). Two structurally distinct and spatially compartmentalized adenylate kinases are expressed from the AK1 gene in mouse brain. Mol. Cell. Biochem.256-257, 59–72. doi: 10.1023/B:MCBI.0000009859.15267.db

  • 20

    KajiroM.HirotaR.NakajimaY.KawanowaK.So-MaK.ItoI.et al. (2009). The ubiquitin ligase CHIP acts as an upstream regulator of oncogenic pathways. Nat. Cell Biol.11, 312–319. doi: 10.1038/ncb1839

  • 21

    KandelE. S.NudlerE. (2002). Template switching by RNA polymerase II in vivo: evidence and implications from a retroviral system. Mol. Cell. 10 (6), 1495–1502. doi: 10.1016/S1097-2765(02)00777-3

  • 22

    KnippaK.PetersonD. O. (2013). Fidelity of RNA polymerase II transcription: role of Rbp9 in error detection and proofreading. Biochemistry52, 7807–7817. doi: 10.1021/bi4009566

  • 23

    Księżakowska-ŁakomaK.ŻyłaM.WilczyńskiJ. R. (2014). Mitochondrial dysfunction in cancer. Przeglad menopauzalny = Menopause Rev.13 (2), 136–144. doi: 10.5114/pm.2014.42717

  • 24

    KumarS.RazzaqS. K.VoA. D.GautamM.LiH. (2016). Identifying fusion transcripts using next generation sequencing. Wiley Interdiscip. Rev. RNA7 (6), 811–823. doi: 10.1002/wrna.1382

  • 25

    López-NievaP.Fernández-NavarroP.Graña-CastroO.Andrés-LeónE.SantosJ.Villa-MoralesM.et al. (2019). Detection of novel fusion-transcripts by RNA-Seq in T-cell lymphoblastic lymphoma. Sci. Rep. 9, 5179. doi: 10.1038/s41598-019-41675-3

  • 26

    LöytynojaA.GoldmanN. (2017). Short template switch events explain mutation clusters in the human genome. Genome Res. 27 (6), 1039–1049. doi: 10.1101/gr.214973.116

  • 27

    LeeH. R.JohnsonK. A. (2006). Fidelity of the human mitochondrial DNA polymerase. J. Biol. Chem.281, 36236–36240. doi: 10.1074/jbc.M607964200

  • 28

    LeeJ. A.CarvalhoC. M. B.LupskiJ. R. (2007). A DNA replication mechanism for generating nonrecurrent rearrangements associated with genomic disorders. Cell.131(7), 1235–1247. doi: 10.1016/j.cell.2007.11.037

  • 29

    LeeS. Y.JoungJ. G.ParkC. H.ParkJ. H.KimJ. H. (2015). RCARE: RNA Sequence Comparison and Annotation for RNA Editing. BMC Med. Genomics8 (2), S8. doi: 10.1186/1755-8794-8-S2-S8

  • 30

    LiM.WangI. X.LiY.BruzelA.RichardsA. L.ToungJ. M.et al. (2011). Widespread RNA and DNA sequence differences in the human transcriptome. Science333 (6038), 53–58. doi: 10.1126/science.1207018

  • 31

    LiL.ZengQ.BhutkarA.GalvánJ. A.KaramitopoulouE.NoordermeerD.et al. (2018). GKAP acts as a genetic modulator of NMDAR signaling to govern invasive tumor growth. Cancer Cell33 (4), 736–751. doi: 10.1016/j.ccell.2018.02.011

  • 32

    LinC. S.LiuL. T.OuL. H.PanS. C.LinC. I.WeiY. H. (2018). Role of mitochondrial function in the invasiveness of human colon cancer cells. Oncol. Rep. 39 (1), 316–330. doi: 10.3892/or.2017.6087

  • 33

    LiuD.YinB.WangQ.JuW.ChenY.QiuH.et al. (2012). Cytoplasmic Poly(A) binding protein 4 is highly expressed in human colorectal cancer and correlates with better prognosis. J. Genet. Genomics. 39 (8), 369–374 doi: 10.1016/j.jgg.2012.05.007

  • 34

    MaY.ChenY.PetersenI. (2017). Expression and epigenetic regulation of cystatin B in lung cancer and colorectal cancer. Pathol. Res. Pract. 213 (12), 1568–1574. doi: 10.1016/j.prp.2017.06.007

  • 35

    MichelC. J.SeligmannH. (2014). Bijective transformation circular codes and nucleotide exchanging RNA transcription. BioSystems. 118 (1), 39–50. doi: 10.1016/j.biosystems.2014.02.002

  • 36

    Modica-NapolitanoJ. S.SinghK. K. (2004). Mitochondrial dysfunction in cancer. Mitochondrion. 4 (5–6 SPEC. ISS.), 755–762. doi: 10.1016/j.mito.2004.07.027

  • 37

    MorgulisA.CoulourisG.RaytselisY.MaddenT. L.AgarwalaR.SchäfferA. A. (2008). Database indexing for production MegaBLAST searches. Bioinformatics24 (16), 1757–1764. doi: 10.1093/bioinformatics/btn322

  • 38

    NetoE. D.CorreaR. G.Verjovski-AlmeidaS.BrionesM. R. S.NagaiM. A.Da SilvaW.et al. (2000). Shotgun sequencing of the human transcriptome with ORF expressed sequence tags. Proc. Natl. Acad. Sci. U. S. A. 97, 3491–3496. doi: 10.1073/pnas.97.7.3491

  • 39

    NinioJ. (1991). Connections between translation, transcription and replication error-rates. Biochimie.73, 1517–1523. doi: 10.1016/0300-9084(91)90186-5

  • 40

    ParejaF.Da Cruz PaulaA.MurrayM. P.HoangT.Gularte-MéridaR.BrownD.et al. (2019). Recurrent MED12 exon 2 mutations in benign breast fibroepithelial lesions in adolescents and young adults. J. Clin. Pathol. 72 (3), 258–262. doi: 10.1136/jclinpath-2018-205570

  • 41

    ParkE.WilliamsB.WoldB. J.MortazaviA. (2012). RNA editing in the human ENCODE RNA-seq data. Genome Res.22, 1626–1633. doi: 10.1101/gr.134957.111

  • 42

    PiovesanA.CaracausiM.AntonarosF.PelleriM. C.VitaleL. (2016). GeneBase 1.1: a tool to summarize data from NCBI gene datasets and its application to an update of human gene statistics. Database J. Biol. Database Curation. 2016, 1–13. doi: 10.1093/database/baw153

  • 43

    PorathH. T.CarmiS.LevanonE. Y. (2014). A genome-wide map of hyper-edited RNA reveals numerous new sites. Nat. Commun. 5, 4726. doi: 10.1038/ncomms5726

  • 44

    RuckovaE.MullerP.NenutilR.VojtesekB. (2012). Alterations of the Hsp70/Hsp90 chaperone and the HOP/CHIP co-chaperone system in cancer. Cell. Mol. Biol. Lett.17, 446–458. doi: 10.2478/s11658-012-0021-8

  • 45

    SchaubM.KellerW. (2002). RNA editing by adenosine deaminases generates RNA and protein diversity. Biochimie. 84 (8), 791–803. doi: 10.1016/S0300-9084(02)01446-3

  • 46

    SeligmannH.RaoultD. (2018). Stem-loop RNA hairpins in giant viruses: Invading rRNA-like repeats and a template free RNA. Front. Microbiol. 9, 101. doi: 10.3389/fmicb.2018.00101

  • 47

    SeligmannH.WarthiG. (2019). Chimeric translation for mitochondrial peptides: regular and expanded codons. Comput. Struct. Biotech. J.17, 1195–1202. doi: 10.1016/j.csbj.2019.08.006

  • 48

    SeligmannH. (2012). Overlapping genes coded in the 3'-to-5'-direction in mitochondrial genes and 3'-to-5' polymerization of non-complementary RNA by an ‘invertase'. J. Theor. Biol.315, 38–52. doi: 10.1016/j.jtbi.2012.08.044

  • 49

    SeligmannH. (2013a). “Replicational Mutation Gradients, Dipole Moments, Nearest Neighbour Effects and DNA Polymerase Gamma Fidelity in Human Mitochondrial Genomes,” in The Mechanisms of DNA Replication. Ed. StuartD. (London: InTech, chpater10), 257–286. doi: 10.5772/51245

  • 50

    SeligmannH. (2013b). Polymerization of non-complementary RNA: Systematic symmetric nucleotide exchanges mainly involving uracil produce mitochondrial RNA transcripts coding for cryptic overlapping genes. BioSystems111, 156–174. doi: 10.1016/j.biosystems.2013.01.011

  • 51

    SeligmannH. (2013c). Systematic asymmetric nucleotide exchanges produce human mitochondrial RNAs cryptically encoding for overlapping protein coding genes. J. Theor. Biol.324, 1–20. doi: 10.1016/j.jtbi.2013.01.024

  • 52

    SeligmannH. (2014a). Species radiation by DNA replication that systematically exchanges nucleotides?J. Theor. Biol.363, 216–222. doi: 10.1016/j.jtbi.2014.08.036

  • 53

    SeligmannH. (2014b). Mitochondrial swinger replication: DNA replication systematically exchanging nucleotides and short 16S ribosomal DNA swinger inserts. BioSystems125, 22–31. doi: 10.1016/j.biosystems.2014.09.012

  • 54

    SeligmannH. (2015a). Swinger RNAs with sharp switches between regular transcription and transcription systematically exchanging ribonucleotides: Case studies. BioSystems135, 1–8. doi: 10.1016/j.biosystems.2015.07.003

  • 55

    SeligmannH. (2015b). Sharp switches between regular and swinger mitochondrial replication: 16S rDNA systematically exchanging nucleotides A<- > T+C<- > G in the mitogenome of Kamimuria wangi. Mitochondrial DNA27 (4), 2440–2446. doi: 10.3109/19401736.2015.1033691

  • 56

    SeligmannH. (2015c). Codon expansion and systematic transcriptional deletions produce tetra-, pentacoded mitochondrial peptides. J. Theor. Biol.387, 154–165. doi: 10.1016/j.jtbi.2015.09.030

  • 57

    SeligmannH. (2016a). Natural chymotrypsin-like-cleaved human mitochondrial peptides confirm tetra-, pentacodon, non-canonical RNA translations. BioSystems147, 78–93. doi: 10.1016/j.biosystems.2016.07.010

  • 58

    SeligmannH. (2016b). Translation of mitochondrial swinger RNAs according to tri-, tetra- and pentacodons. BioSystems140, 38–48. doi: 10.1016/j.biosystems.2015.11.009

  • 59

    SeligmannH. (2016c). Unbiased mitoproteome analyses confirm non-canonical RNA, expanded codon translations. Comput. Struct. Biotechnol. J. 14, 391–403. doi: 10.1016/j.csbj.2016.09.004

  • 60

    SeligmannH. (2016d). Chimeric mitochondrial peptides from contiguous regular and swinger RNA. Comput. Struct. Biotechnol. J.14, 283–297. doi: 10.1016/j.csbj.2016.06.005

  • 61

    SeligmannH. (2016e). Swinger RNA self-hybridization and mitochondrial non-canonical swinger transcription, transcription systematically exchanging nucleotides. J. Theor. Biol.399, 84–91. doi: 10.1016/j.jtbi.2016.04.007

  • 62

    SeligmannH. (2016f). Systematically frameshifting by deletion of every 4th or 4th and 5th nucleotides during mitochondrial transcription: RNA self-hybridization regulates delRNA expression. Biosystems142-143, 43–51. doi: 10.1016/j.biosystems.2016.03.009

  • 63

    SeligmannH. (2017a). Natural mitochondrial proteolysis confirms transcription systematically exchanging/deleting nucleotides, peptides coded by expanded codons. J. Theor. Biol.414, 76–90. doi: 10.1016/j.jtbi.2016.11.021

  • 64

    SeligmannH. (2017b). Reviewing evidence for systematic transcriptional deletions, nucleotide exchanges, and expanded codons, and peptide clusters in human mitochondria. BioSystems160, 10–24. doi: 10.1016/j.biosystems.2017.08.002

  • 65

    SeligmannH. (2018). Bijective codon transformations show genetic code symmetries centered on cytosine's coding properties. Theory Biosci137, 17–31. doi: 10.1007/s12064-017-0258-x

  • 66

    SinghA.ZahraS.DasD.KumarS. (2019). “AtFusionDB: a database of fusion transcripts in Arabidopsis thaliana. Database2019, 1–9. doi: 10.1093/database/bay135

  • 67

    StrathernJ. N.JinD. J.CourtD. L.KashlevM. (2012). Isolation and characterization of transcription fidelity mutants. Biochim. Biophys. Acta - Gene Regul. Mech. 1819, 694–699. doi: 10.1016/j.bbagrm.2012.02.005

  • 68

    TarantulV.NikolaevA.HannigH.KalmyrzaevB.MuchoyanI.MaximovV.et al. (2001). Detection of abundantly transcribed genes and gene translocation in human immunodeficiency virus - Associated non-hodgkin's lymphoma. Neoplasia3 (2), 132–142. doi: 10.1038/sj.neo.7900137

  • 69

    VasseurS.MalicetC.CalvoE. L.DagornJ. C.IovannaJ. L. (2005). Gene expression profiling of tumours derived from rasv12/E1A-transformed mouse embryonic fibroblasts to identify genes required for tumour development. Mol. Cancer4 (1), 4. doi: 10.1186/1476-4598-4-4

  • 70

    WangS.WuX.ZhangJ.ChenY.XuJ.XiaX.et al. (2013). CHIP functions as a novel suppressor of tumour angiogenesis with prognostic significance in human gastric cancer. Gut.62, 496–508. doi: 10.1136/gutjnl-2011-301522

  • 71

    WangI. X.CoreL. J.KwakH.BradyL.BruzelA.McDanielL.et al. (2014). RNA-DNA differences are generated in human cells within seconds after RNA exits polymerase II. Cell Rep.6, 906–915. doi: 10.1016/j.celrep.2014.01.037

  • 72

    WangT.YangJ.XuJ.LiJ.CaoZ.ZhouL.et al. (2014a). CHIP is a novel tumor suppressor in pancreatic cancer through targeting EGFR. Oncotarget.5, 1969–1986. doi: 10.18632/oncotarget.1890

  • 73

    WangY.RenF.WangY.FengY.WangD.JiaB.et al. (2014b). CHIP/Stub1 functions as a tumor suppressor and represses NF-κB-mediated signaling in colorectal cancer. Carcinogenesis35, 983–991. doi: 10.1093/carcin/bgt393

  • 74

    WangI. X.GrunseichC.ChungY. G.KwakH.RamrattanG.ZhuZ.et al. (2016). RNA-DNA sequence differences in Saccharomyces cerevisiae. Genome Res.26, 1544–1554. doi: 10.1101/gr.207878.116

  • 75

    WarthiG.SeligmannH. (2018). “Swinger RNAs in the Human Mitochondrial Transcriptome,” in In mitochondrial DNA-new insights. Eds. SeligmannH.WarthiG., (London) 79–92. Chapter 4. doi: 10.5772/intechopen.80805

  • 76

    WarthiG.SeligmannH. (2019). Transcripts with systematic nucleotide deletion of 1-12 nucleotide in human mitochondrion suggest potential non-canonical transcription. PloS One14, e0217356. doi: 10.1371/journal.pone.0217356

  • 77

    WarthiG.FournierPE.SeligmannH. (2019). Identification of noncanonical transcripts produced by systematic nucleotide exchanges in HIV-associated centroblastic lymphoma. DNA Cell Biol. doi: 10.1089/dna.2019.5066 [Epub ahead of print]

  • 78

    XieJ.UbangoJ.BanY.ChakravartiD.KimJ. J.WeiJ. J. (2018). Comparative analysis of AKT and the related biomarkers in uterine leiomyomas with MED12, HMGA2, and FH mutations. Genes Chromosom. Cancer57 (10), 485–494. doi: 10.1002/gcc.22643

  • 79

    YingZ.HaiyanG.HaidongG. (2013). BAG5 regulates PTEN stability in MCF-7 cell line. BMB Rep.46, 490–494. doi: 10.5483/BMBRep.2013.46.10.268

  • 80

    ZengM.LiF.WangL.ChenC.HuangX.WuX.et al. (2018). Downregulated cytoplasmic polyadenylation element-binding protein-4 is associated with the carcinogenesis of head and neck squamous cell carcinoma. Oncol. Lett.15 (3), 3226–3232. doi: 10.3892/ol.2017.7661

  • 81

    ZhangZ.SchwartzS.WagnerL.MillerW. (2000). A greedy algorithm for aligning DNA sequences. J. Comput. Biol. 7 (1–2), 203–214. doi: 10.1089/10665270050081478

  • 82

    ZhangJ.ShiZ. F.HuangJ. X.ZouX. G. (2016). CSTB downregulation promotes cell proliferation and migration and suppresses apoptosis in gastric cancer SGC-7901 cell line. Oncol. Res. 24 (6), 487–494. doi: 10.3727/096504016X14685034103752

  • 83

    ZhouY. N.LubkowskaL.HuiM.CourtC.ChenS.CourtD. L.et al. (2013). Isolation and characterization of RNA polymerase rpoB mutations that alter transcription slippage during elongation in Escherichia coli. J. Biol. Chem.288, 2700–2710. doi: 10.1074/jbc.M112.429464

Summary

Keywords

swinger RNAs, systematic nucleotide exchanges, transcriptome, cDNA, cancer

Citation

Warthi G, Fournier P-E and Seligmann H (2020) Systematic Nucleotide Exchange Analysis of ESTs From the Human Cancer Genome Project Report: Origins of 347 Unknown ESTs Indicate Putative Transcription of Non-Coding Genomic Regions. Front. Genet. 11:42. doi: 10.3389/fgene.2020.00042

Received

28 October 2019

Accepted

15 January 2020

Published

11 February 2020

Volume

11 - 2020

Edited by

Dapeng Wang, University of Leeds, United Kingdom

Reviewed by

Rachita Yadav, Harvard Medical School, United States; Hauke Busch, Universität zu Lübeck, Germany

Updates

Copyright

*Correspondence: Ganesh Warthi,

This article was submitted to Bioinformatics and Computational Biology, a section of the journal Frontiers in Genetics

Disclaimer

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Outline

Figures

Cite article

Copy to clipboard


Export citation file


Share article

Article metrics